Sign up Australia
Proactive Investors - Run By Investors For Investors

Phylogica patents peptide technology to develop cell-penetrating drugs

Phylogica patents peptide technology to develop cell-penetrating drugs

Phylogica (ASX:PYC) has patented an improvement to its Phylomer peptide platform that will allow more efficient screening of its library of billions of naturally occurring peptides and identify those with the highest potential to target disease proteins inside the cells.

To develop a new generation of therapies, the peptides need to be able to deliver biologics drugs to cells where most targets are. To do this effectively, they need to penetrate natural cell membranes; target particular parts of the cell such as nuclei and ensure that drug cargos are not trapped in endosomes.

There is a significant requirement for technologies that improve the efficiency of the delivery of large therapeutic molecules such as proteins into cells as cell membranes can be major impediments.

Phylogica’s Endosomal Escape Trap enables the efficient identification of Phylomer cell-penetrating peptide-drug conjugates that not only deliver the therapeutic payload across the cell membrane, but also efficiently escape from the endosome so that the drug can have a therapeutic effect.

It is partnering with Genentech, a member of Roche Group (VTR:ROG); MedImmune- the biologics arm of AstraZeneca (LON:AZN); Pfizer and Janssen Biotech.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Register here to be notified of future PYC Company articles
View full PYC profile


October 06 2015
November 25 2014
November 07 2013

Related Articles

picture of someone with head pain
December 08 2016
Its strategy is to develop cell lines for "off the-shelf" therapies to treat serious conditions
September 07 2016
It means Futura now has a differentiated product in a market worth US$5bn that , currently dominated by top-selling drugs, such as Viagra and Cialis, that have limitations.
picture of drug research
“The positive results from this feasibility award may lead to other opportunities to secure additional funding awards to advance the programme further," Dr John Reader, Sareum's chief scientific officer said.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.